Fosinoprilat alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 182-186

  Yang, Shuansuo ^a   Li, Ruogu ^b   Qu, Xinkai ^b   Tang, Lei ^c   Ge, Guanghao ^a   Fang, Weiyi ^b   Qiao, Zengyong ^a   Ma, Jiangwei ^a   Hou, Yuemei ^a   Liu, Huajin ^a  

^a Fengxian Central Hospital   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anti atherosclerosis; Fosinoprilat; Lipopolysacharides; Toll like receptors

Indexed keywords

FOSINOPRILAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFLAMMATION; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; WESTERN BLOTTING;

ANTI-ATHEROSCLEROSIS; FOSINOPRILAT; LIPOPOLYSACHARIDES; TOLL-LIKE RECEPTORS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOTTING, WESTERN; CELL LINE; FLOW CYTOMETRY; FOSINOPRIL; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MONOCYTES; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884190225     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.06.009     Document Type: Article

References (26)

1. Saikku P., Leinonen M., Mattila K., Ekman M.R., Nieminen M.S., Makela P.H., Huttunen J.K., Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988, 2:983-986.
2. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
3. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 2002, 91:281-291.
4. Read M.A., Collins T., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-KB and cytokine inducible enhancers. FASEB J. 1995, 9:899-909.
5. Walton K.A., Hsieh X., Gharavi N., Wang S., Wang G., Yeh M., Cole A.L., Berliner J.A. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 2003, 278:29661-29666.
6. van der Valk F.M., van Wijk D.F., Stroes E.S. Novel anti-inflammatory strategies in atherosclerosis. Curr. Opin. Lipidol. 2012, 23:532-539.
7. Niessner A., Steiner S., Speidl W.S., Pleiner J., Seidinger D., Maurer G., Goronzy J.J., Weyand C.M., Kopp C.W., Huber K., Wolzt M., Wojta J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413.
8. Riosvelasco A.C., Dasu M.R., Jialal I. Candesartan inhibits toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 2009, 202:76-83.
9. Pouwels K.B., Visser S.T., Hak E. Effect of pravastatin and fosinopril on recurrent urinary tract infections. J. Antimicrob. Chemother 2012, 68:708-714.
10. Tang T.F., Zhou Q.L., Zhu L.L., Tang R., Ao X. Effects of fosinopril and losartan on the expression of toll- like receptor 4 in renal tubular epithelia cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008, 33:958-965.
11. Bjorkbacka H., Fredrikson G.N., Nilsson J. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence. Atherosclerosis 2012, 227:9-17.
12. Luo M.J., Thieringer R., Springer M.S., Wright S.D., Hermanowski-Vosatka A., Plump A., Balkovec J.M., Cheng K., Ding G.J., Kawka D.W., Koo G.C., Le Grand C.B., Luo Q., Maletic M.M., Malkowitz L., Shah K., Singer I., Waddell S.T., Wu K.K., Yuan J., Zhu J., Stepaniants S., Yang X., Lum P.Y., Wang I.M. 11 beta-HSD1 inhibition reduces atherosclerosis in mice by altering pro-inflammatory gene expression in the vasculature. Physiol. Genomics 2013, 45:47-57.
13. Potteaux S., Combadière C., Rodero M., Simon T., Pezard A., Esposito B., Merval R., Proudfoot A., Tedgui A., Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 2008, 117:1649-1657.
14. -/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008, 117:1642-1648.
15. Li M.W., Ebrahimian T., Lemarié C.A., Simeone S.M., Pagano P.J., Gaestel M., Paradis P., Wassmann S., Schiffrin E.L. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 2011, 57:245-254.
16. Sriramula S., Cardinale J.P., Lazartigues E., Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc. Res. 2011, 92:401-408.
17. Jin H.-Y., Song B., Oudit G.Y., Davidge S.T., Yu H.-M., Jiang Y.-Y., Gao P.-J., Zhu D.-L., Ning G., Kassiri Z. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 2012, 7:e38502.
18. Lipton B.A., Ylä-Herttuala S., Rosenfeld M.E., Särkioja T., Yoshimura T., Leonard E.J., Witztum J.L., Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 1991, 88:5252-5256.
19. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2137-2142.
20. Lu W., Liu F., Qian Q., Qi W., Hu J., Feng B. Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to Type 2 diabetes and coronary artery disease. J. Biomed. Biotechnol. 2012, 2012:373945.
21. Ameziane N., Beillat T., Verpillat P., Chollet-Martin S., Aumont M.C., Seknadji P., Lamotte M., Lebret D., Ollivier V., de Prost D. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 2003, 23:e61-64.
22. Hegener H., Zee R.Y., Gould J. TLR4 Asp299Gly polymorphism and risk of atherothrombosis. Stroke 2005, 36:154-157.
23. Methe H., Kim J.O., Kofler S., Weis M., Nabauer M., Koglin J. Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005, 111:2654-2661.
24. Xie P., Cao Y.-s., Su P., Li Y.-h., Gao Z.-l., Borst M.M. Expression of toll-like receptor 4, tumor necrosis factor-alpha, matrix metalloproteinase-9 and effects of benazepril in patients with acute coronary syndromes. Clin. Med. Insights Cardiol. 2010, 4:89.
25. Moutzouri E., Tellis C.C., Rousouli K., Liberopoulos E.N., Milionis H.J., Elisaf M.S., Tselepis A.D. Effect of simvastatin or its combination with ezetimibe on toll-like receptor expression and lipopolysacharide - induced cytokine production in monocytes of hypercholesterolemic patients. Atherosclerosis 2012, 225:381-387.
26. Gonzalez-Teran B., Cortes J.R., Manieri E., Matesanz N., Verdugo A., Rodriguez M.E., Gonzalez-Rodriguez A., Valverde A., Martin P., Davis R.J., Sabio G. Eukaryotic elongation factor 2 controls TNF-alpha translation in LPS-induced hepatitis. J. Clin. Invest. 2013, 123:164-178.